8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Mar 6, 2026·SEC
Material company update
Mar 5, 2026·SEC
Pacific Biosciences of California, Inc.(PACB)Earnings, Financials & Key Ratios
PACB•NASDAQ
Price updated Jun 19, 2026
AboutPacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.Show more
- Revenue$160M+3.9%
- EBITDA-$53M+87.5%
- Net Income-$546M-76.3%
- EPS (Diluted)-1.82-70.1%
- Gross Margin31.67%+30.8%
- EBITDA Margin-32.91%+88.0%
- Operating Margin-348.46%-13.1%
- Net Margin-341.47%-69.7%
- ROE-213.45%-316.1%
PACB Key Insights
Pacific Biosciences of California, Inc. (PACB) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 15.2%
✗Weaknesses
- ✗High debt to equity ratio of 142.0x
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Trading more than 30% below 52-week high
- ✗Expensive at 78.5x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when PACB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PACB Price & Volume
Pacific Biosciences of California, Inc. (PACB) stock price & volume — 10-year historical chart
Loading chart...
PACB Growth Metrics
Pacific Biosciences of California, Inc. (PACB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years5.6%
5 Years15.19%
3 Years7.64%
TTM5.04%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM80.45%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM81.24%
Return on Capital
10 Years-49.41%
5 Years-29.72%
3 Years-37.5%
Last Year-57.96%
PACB Recent Earnings
Pacific Biosciences of California, Inc. (PACB) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 5/12 qtrs (42%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.12+29.4%
$0.17
Rev
$37M-6.9%
$40M
Q1 2026
Feb 12, 2026Metric
Actual
Est
EPS
$0.12+36.8%
$0.19
Rev
$45M+3.7%
$43M
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$0.12+25.0%
$0.16
Rev
$38M-13.8%
$45M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.13+27.8%
$0.18
Rev
$40M-0.5%
$40M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.12vs $0.17+29.4% | $37Mvs $40M-6.9% |
| Q1 2026 | Feb 12, 2026 | $0.12vs $0.19+36.8% | $45Mvs $43M+3.7% |
| Q4 2025 | Nov 5, 2025 | $0.12vs $0.16+25.0% | $38Mvs $45M-13.8% |
| Q3 2025 | Aug 7, 2025 | $0.13vs $0.18+27.8% | $40Mvs $40M-0.5% |
Based on last 12 quarters of dataView full earnings history →
PACB Peer Comparison
Pacific Biosciences of California, Inc. (PACB) competitors in Device suppliers, distribution, and services — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ILMN | 24.6B | 161.93 | 29.71 | -0.78% | 19.43% | 32.84% | 0.94 | |
 BFLY | 2.33B | 8.90 | -28.71 | 18.96% | -73.63% | -36.79% | 0.10 | |
 CDNA | 1.35B | 26.18 | -65.45 | 13.79% | -1.98% | -2.61% | 0.06 | |
 TMO | 172.66B | 464.61 | 26.19 | 3.91% | 15.18% | 13.23% | 0.76 | |
 DHR | 125.4B | 177.17 | 35.15 | 2.9% | 14.89% | 7.06% | 0.35 | |
 A | 35.89B | 127.06 | 27.80 | 6.73% | 19.55% | 20.84% | 0.50 | |
 BIO | 7.63B | 282.44 | 10.13 | 0.65% | 6.52% | 2.4% | 0.21 | |
 BEAM | 3.51B | 34.14 | -42.15 | 120.01% | -49.17% | -5.89% | 0.24 |
Compare PACB vs Peers
Pacific Biosciences of California, Inc. (PACB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PACB Income Statement
Pacific Biosciences of California, Inc. (PACB) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 93.47M | 78.63M | 90.89M | 78.89M | 130.51M | 128.3M | 200.52M | 154.01M | 160M | 160.03M |
Revenue Growth % | 3.04% | -15.88% | 15.6% | -13.2% | 65.43% | -1.69% | 56.29% | -23.19% | 3.89% | 5.04% |
Cost of Goods Sold | 58.81M | 53.53M | 56.31M | 46.33M | 71.65M | 79.27M | 147.74M | 116.73M | 109.33M | 100.69M |
COGS % of Revenue | 62.92% | 68.08% | 61.96% | 58.72% | 54.9% | 61.78% | 73.68% | 75.79% | 68.33% | - |
Gross Profit | 34.66M▲ 0% | 25.1M▼ 27.6% | 34.58M▲ 37.8% | 32.57M▼ 5.8% | 58.86M▲ 80.7% | 49.03M▼ 16.7% | 52.78M▲ 7.6% | 37.28M▼ 29.4% | 50.67M▲ 35.9% | 59.34M▲ 0% |
Gross Margin % | 37.08% | 31.92% | 38.04% | 41.28% | 45.1% | 38.22% | 26.32% | 24.21% | 31.67% | 37.08% |
Gross Profit Growth % | -21.51% | -27.59% | 37.77% | -5.81% | 80.74% | -16.69% | 7.64% | -29.36% | 35.92% | - |
Operating Expenses | 124.44M | 126.08M | 135.12M | 136.95M | 269.3M | 356.23M | 387.25M | 511.6M | 608.24M | 222.12M |
OpEx % of Revenue | 133.14% | 160.36% | 148.66% | 173.59% | 206.34% | 277.65% | 193.12% | 332.17% | 380.13% | - |
Selling, General & Admin | 59.12M | 63.49M | 75.49M | 72.8M | 124.12M | 160.85M | 169.82M | 175.02M | 141.49M | 132.48M |
SG&A % of Revenue | 63.25% | 80.75% | 83.06% | 92.28% | 95.1% | 125.37% | 84.69% | 113.64% | 88.43% | - |
Research & Development | 65.32M | 62.59M | 59.63M | 64.15M | 112.9M | 193M | 187.17M | 134.92M | 97.31M | 87.86M |
R&D % of Revenue | 69.89% | 79.61% | 65.61% | 81.32% | 86.5% | 150.42% | 93.34% | 87.6% | 60.81% | - |
Other Operating Expenses | 516K | 848K | 0 | 0 | 32.27M | 2.38M | 30.26M | 201.66M | 369.44M | 1.83M |
Operating Income | -89.78M▲ 0% | -100.99M▼ 12.5% | -100.55M▲ 0.4% | -104.39M▼ 3.8% | -210.44M▼ 101.6% | -307.2M▼ 46.0% | -334.47M▼ 8.9% | -474.31M▼ 41.8% | -557.56M▼ 17.6% | -162.78M▲ 0% |
Operating Margin % | -96.06% | -128.44% | -110.62% | -132.31% | -161.24% | -239.43% | -166.8% | -307.97% | -348.46% | -101.72% |
Operating Income Growth % | -26.02% | -12.48% | 0.44% | -3.82% | -101.6% | -45.98% | -8.88% | -41.81% | -17.55% | - |
EBITDA | -81.34M | -93.77M | -90.6M | -95.08M | -198.85M | -289.88M | -301.78M | -420.96M | -52.65M | -151.03M |
EBITDA Margin % | -87.03% | -119.26% | -99.68% | -120.52% | -152.36% | -225.93% | -150.5% | -273.33% | -32.91% | -94.38% |
EBITDA Growth % | -20.74% | -15.28% | 3.39% | -4.95% | -109.14% | -45.78% | -4.1% | -39.49% | 87.49% | 62.96% |
D&A (Non-Cash Add-back) | 8.44M | 7.21M | 9.95M | 9.3M | 11.59M | 17.32M | 32.69M | 53.35M | 504.91M | 8.98M |
EBIT | -89.27M | -100.14M | -81.52M | 29.67M | -262.34M | -299.56M | -303.82M | -296.12M | -539.1M | -155.32M |
Net Interest Income | -2.92M | -2.42M | -2.61M | -267K | -12.53M | -14.69M | -14.34M | -13.41M | -6.95M | -3.48M |
Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 2.92M | 2.42M | 2.61M | 267K | 12.53M | 14.69M | 14.34M | 13.41M | 6.95M | 3.48M |
Other Income/Expense | -2.4M | -1.57M | 16.41M | 133.79M | -64.44M | -7.05M | 16.31M | 164.78M | 11.5M | 35.01M |
Pretax Income | -92.19M▲ 0% | -102.56M▼ 11.3% | -84.13M▲ 18.0% | 29.4M▲ 134.9% | -274.87M▼ 1034.8% | -314.25M▼ 14.3% | -318.16M▼ 1.2% | -309.54M▲ 2.7% | -546.06M▼ 76.4% | -127.77M▲ 0% |
Pretax Margin % | -98.63% | -130.44% | -92.57% | 37.27% | -210.61% | -244.92% | -158.67% | -200.98% | -341.28% | -79.84% |
Income Tax | 0 | 848K | 0 | 0 | -93.65M | 0 | -11.42M | 316K | 318K | 804K |
Effective Tax Rate % | 0% | -0.83% | 0% | 0% | 34.07% | 0% | 3.59% | -0.1% | -0.06% | -0.63% |
Net Income | -92.19M▲ 0% | -102.56M▼ 11.3% | -84.13M▲ 18.0% | 29.4M▲ 134.9% | -181.22M▼ 716.3% | -314.25M▼ 73.4% | -306.74M▲ 2.4% | -309.85M▼ 1.0% | -546.38M▼ 76.3% | -128.58M▲ 0% |
Net Margin % | -98.63% | -130.44% | -92.57% | 37.27% | -138.85% | -244.92% | -152.97% | -201.18% | -341.47% | -80.34% |
Net Income Growth % | -23.95% | -11.25% | 17.97% | 134.95% | -716.34% | -73.4% | 2.39% | -1.02% | -76.34% | 80.45% |
Net Income (Continuing) | -92.19M | -102.56M | -84.13M | 29.4M | -181.22M | -314.25M | -306.74M | -309.85M | -546.38M | -128.58M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.87▲ 0% | -0.76▲ 12.6% | -0.51▲ 32.9% | 0.17▲ 133.3% | -0.89▼ 623.5% | -1.40▼ 57.3% | -1.21▲ 13.6% | -1.07▲ 11.6% | -1.82▼ 70.1% | -0.42▲ 0% |
EPS Growth % | -4.82% | 12.64% | 32.89% | 133.33% | -623.53% | -57.3% | 13.57% | 11.57% | -70.09% | 81.24% |
EPS (Basic) | -0.87 | -0.76 | -0.51 | 0.18 | -0.89 | -1.40 | -1.21 | -1.13 | -1.82 | - |
Diluted Shares Outstanding | 105.68M | 135.09M | 152.53M | 174.97M | 204.14M | 224.55M | 253.63M | 288.37M | 299.96M | 305.82M |
Basic Shares Outstanding | 105.68M | 134.95M | 152.53M | 165.19M | 203.62M | 224.55M | 253.63M | 274.49M | 299.96M | 305.82M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
PACB Balance Sheet
Pacific Biosciences of California, Inc. (PACB) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 101.62M | 131.66M | 81.05M | 355.59M | 1.1B | 852.07M | 742.05M | 495.68M | 375.03M | 369.52M |
Cash & Short-Term Investments | 62.87M | 102.35M | 49.1M | 318.81M | 1.04B | 772.32M | 631.42M | 389.93M | 279.51M | 275.98M |
Cash Only | 62.87M | 18.84M | 29.63M | 81.61M | 460.73M | 325.09M | 179.91M | 55.37M | 63.71M | 56.29M |
Short-Term Investments | 0 | 83.51M | 19.47M | 237.2M | 583.67M | 447.23M | 451.5M | 334.56M | 215.8M | 219.69M |
Accounts Receivable | 13.43M | 8.6M | 15.27M | 16.84M | 24.24M | 18.79M | 36.62M | 27.52M | 35.45M | 29.35M |
Days Sales Outstanding | 52.46 | 39.9 | 61.31 | 77.9 | 67.79 | 53.44 | 66.65 | 65.23 | 80.86 | 72.8 |
Inventory | 23.07M | 17.88M | 13.31M | 14.23M | 24.6M | 50.38M | 56.68M | 58.76M | 49.28M | 51.02M |
Days Inventory Outstanding | 143.15 | 121.9 | 86.28 | 112.11 | 125.31 | 231.98 | 140.02 | 183.72 | 164.54 | 187.87 |
Other Current Assets | 0 | 0 | 300K | 836K | 500K | 300K | 17.34M | 19.47M | 10.79M | 13.16M |
Total Non-Current Assets | 42.47M | 38.62M | 66.94M | 58.39M | 905.84M | 915.01M | 1B | 764.77M | 409.05M | 412.85M |
Property, Plant & Equipment | 37.92M | 34.07M | 62.9M | 54.85M | 79.12M | 81.34M | 69.03M | 46.6M | 65.84M | 65.22M |
Fixed Asset Turnover | 2.46x | 2.31x | 1.45x | 1.44x | 1.65x | 1.58x | 2.91x | 3.31x | 2.43x | 2.44x |
Goodwill | 0 | 0 | 0 | 0 | 409.97M | 409.97M | 462.26M | 317.76M | 317.76M | 317.76M |
Intangible Assets | 0 | 0 | 0 | 0 | 410.98M | 410.25M | 456.98M | 389.57M | 15.12M | 14.1M |
Long-Term Investments | 4.5M | 4.5M | 0 | 0 | 0 | 0 | 0 | 0 | 1.53M | 3.1M |
Other Non-Current Assets | 45K | 43K | 4.04M | 3.54M | 5.76M | 13.45M | 15.7M | 10.84M | 8.79M | 14.19M |
Total Assets | 144.08M▲ 0% | 170.28M▲ 18.2% | 147.99M▼ 13.1% | 413.98M▲ 179.7% | 2.01B▲ 384.8% | 1.77B▼ 12.0% | 1.75B▼ 1.2% | 1.26B▼ 27.8% | 784.08M▼ 37.8% | 782.37M▲ 0% |
Asset Turnover | 0.65x | 0.46x | 0.61x | 0.19x | 0.07x | 0.07x | 0.11x | 0.12x | 0.20x | 0.20x |
Asset Growth % | 4.5% | 18.18% | -13.09% | 179.74% | 384.8% | -11.95% | -1.19% | -27.81% | -37.79% | -136.83% |
Total Current Liabilities | 22.32M | 20.35M | 49.15M | 38.5M | 71.71M | 263.33M | 95.03M | 66.3M | 54.42M | 65.36M |
Accounts Payable | 9.09M | 6.74M | 8.37M | 3.58M | 11M | 12.03M | 15.06M | 16.59M | 20.77M | 13.61M |
Days Payables Outstanding | 56.44 | 45.93 | 54.24 | 28.2 | 56.04 | 55.38 | 37.21 | 51.87 | 69.34 | 59.63 |
Short-Term Debt | 0 | 0 | 15.87M | 0 | 1.61M | 1.84M | 490K | 0 | 448K | 277K |
Deferred Revenue (Current) | 6.32M | 6.54M | 7.61M | 8.72M | 10.98M | 30.5M | 16.34M | 13.86M | 0 | 31.19M |
Other Current Liabilities | 5.65M | 5.09M | 225K | 4.52M | 4.15M | 175.5M | 7.84M | 3.22M | 32.75M | 35.14M |
Current Ratio | 4.55x | 6.47x | 1.65x | 9.24x | 15.36x | 3.24x | 7.81x | 7.48x | 6.89x | 5.65x |
Quick Ratio | 3.52x | 5.59x | 1.38x | 8.87x | 15.01x | 3.04x | 7.21x | 6.59x | 5.99x | 4.87x |
Cash Conversion Cycle | 139.17 | 115.87 | 93.35 | 161.81 | 137.06 | 230.04 | 169.46 | 197.07 | 176.06 | 201.04 |
Total Non-Current Liabilities | 35.66M | 35.87M | 43.91M | 39.99M | 1.14B | 940.85M | 949.68M | 687.55M | 724.32M | 714.64M |
Long-Term Debt | 13.63M | 14.66M | 0 | 0 | 896.07M | 896.68M | 892.24M | 647.49M | 702.42M | 644.11M |
Capital Lease Obligations | 0 | 0 | 41.96M | 37.67M | 49.97M | 41.07M | 31.61M | 14.91M | 57.04M | 222.43M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | -25.05M | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 14.64M | 13.78M | 0 | 752K | 198.24M | 1.3M | 20.3M | 19.25M | -55.01M | 7.98M |
Total Liabilities | 57.98M | 56.21M | 93.07M | 78.49M | 1.22B | 1.2B | 1.04B | 753.85M | 778.73M | 780M |
Total Debt | 13.63M | 14.66M | 61.67M | 42M | 955.36M | 948.48M | 933.93M | 672.43M | 759.46M | 703.39M |
Net Debt | -49.24M | -4.18M | 32.05M | -39.61M | 494.63M | 623.39M | 754.02M | 617.06M | 695.75M | 647.1M |
Debt / Equity | 0.16x | 0.13x | 1.12x | 0.13x | 1.21x | 1.68x | 1.33x | 1.33x | 141.98x | 297.29x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -4.66x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -4.28x |
Interest Coverage | -30.56x | -41.33x | -31.22x | 111.12x | -20.94x | -20.39x | -21.18x | -22.08x | -77.52x | -44.67x |
Total Equity | 86.1M▲ 0% | 114.06M▲ 32.5% | 54.92M▼ 51.9% | 335.49M▲ 510.9% | 790.99M▲ 135.8% | 562.9M▼ 28.8% | 701.3M▲ 24.6% | 506.59M▼ 27.8% | 5.35M▼ 98.9% | 2.37M▲ 0% |
Equity Growth % | 1.69% | 32.47% | -51.85% | 510.91% | 135.77% | -28.84% | 24.59% | -27.76% | -98.94% | -375.92% |
Book Value per Share | 0.81 | 0.84 | 0.36 | 1.92 | 3.87 | 2.51 | 2.77 | 1.76 | 0.02 | 0.01 |
Total Shareholders' Equity | 86.1M | 114.06M | 54.92M | 335.49M | 790.99M | 562.9M | 701.3M | 506.59M | 5.35M | 2.37M |
Common Stock | 116K | 150K | 153K | 192K | 221K | 227K | 268K | 294K | 302K | 311K |
Retained Earnings | -879.73M | -982.11M | -1.07B | -1.04B | -1.22B | -1.53B | -1.84B | -2.15B | -2.7B | -2.7B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -32K | -36K | 5K | 85K | -1.09M | -4.76M | 219K | 422K | 457K | -147K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PACB Cash Flow Statement
Pacific Biosciences of California, Inc. (PACB) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -67.52M | -66.43M | -78.31M | 19.5M | -111.18M | -263.21M | -266.55M | -206.06M | -111.21M | -111.84M |
Operating CF Margin % | -72.24% | -84.49% | -86.16% | 24.72% | -85.19% | -205.15% | -132.93% | -133.79% | -69.5% | - |
Operating CF Growth % | 0.6% | 1.61% | -17.89% | 124.9% | -670.07% | -136.74% | -1.27% | 22.69% | 46.03% | 141.06% |
Net Income | -92.19M | -102.56M | -84.13M | 29.4M | -181.22M | -314.25M | -306.74M | -309.85M | -546.38M | -128.58M |
Depreciation & Amortization | 8.44M | 7.21M | 9.95M | 9.3M | 11.59M | 17.32M | 32.69M | 53.34M | 0 | 17.69M |
Stock-Based Compensation | 20.35M | 23.15M | 16.4M | 17.53M | 80.73M | 78.61M | 0 | 0 | 0 | 9.59M |
Deferred Taxes | 653K | -925K | -735K | -107K | -93.65M | 0 | -11.42M | -205K | 0 | 0 |
Other Non-Cash Items | 1.25M | 1.02M | -16.79M | -33.87M | 50.37M | 9.08M | 77.88M | 91.24M | 430.73M | -20.55M |
Working Capital Changes | -6.03M | 5.67M | -3M | -2.76M | 21M | -53.97M | -58.96M | -40.58M | 4.44M | 10M |
Change in Receivables | -2.01M | 4.84M | -6.67M | -1.6M | -7.17M | 5.46M | -17.83M | 9.09M | -7.92M | 2.29M |
Change in Inventory | -8.44M | 3.62M | 3.92M | -1.1M | -12.43M | -33.91M | -13.84M | -8.32M | -1.42M | -2.09M |
Change in Payables | 764K | -2.24M | 1.71M | -5.07M | 6.36M | 1.02M | 206K | 1.41M | 2.48M | -315K |
Cash from Investing | -1.55M | -38.41M | 62.05M | -219.32M | -678.53M | 116.08M | 4.6M | 124M | 115.45M | 106.07M |
Capital Expenditures | -10.43M | -1.85M | -2.84M | -1.04M | -5.93M | -16.93M | -8.84M | -6.19M | -2.71M | -9.37M |
CapEx % of Revenue | 11.16% | 2.36% | 3.12% | 1.32% | 4.54% | 13.19% | 4.41% | 4.02% | 1.7% | 5.85% |
Acquisitions | 41K | 0 | -64.88M | 0 | -319.79M | 179K | -102K | 0 | 0 | 50M |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 41K | -36.56M | 64.88M | 0 | 0 | -179K | 0 | 0 | -5M | -1.9M |
Cash from Financing | 68.81M | 107.18M | 26.55M | 251.84M | 1.17B | 9.62M | 116.27M | -42.99M | 3.43M | 2.91M |
Debt Issued (Net) | -4.5M | 0 | 0 | -16M | 895.17M | -1.61M | -1.84M | -50.69M | 0 | 0 |
Equity Issued (Net) | 64.39M | 97.53M | 8.55M | 187.48M | 294.85M | 11.23M | 204.52M | 7.7M | 3.43M | 2.91M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 8.91M | 9.65M | 18M | 80.36M | -20.44M | 0 | -86.41M | 0 | 0 | 0 |
Net Change in Cash | -258K▲ 0% | 2.34M▲ 1005.8% | 10.28M▲ 340.0% | 52.02M▲ 405.9% | 379.87M▲ 630.2% | -137.51M▼ 136.2% | -145.18M▼ 5.6% | -124.15M▲ 14.5% | 7.67M▲ 106.2% | -2.9M▲ 0% |
Free Cash Flow | -77.95M▲ 0% | -68.28M▲ 12.4% | -81.15M▼ 18.8% | 18.46M▲ 122.8% | -117.11M▼ 734.3% | -280.14M▼ 139.2% | -275.39M▲ 1.7% | -212.25M▲ 22.9% | -113.92M▲ 46.3% | -116.21M▲ 0% |
FCF Margin % | -83.4% | -86.85% | -89.28% | 23.4% | -89.73% | -218.34% | -137.34% | -137.81% | -71.2% | -72.62% |
FCF Growth % | -2.38% | 12.4% | -18.84% | 122.75% | -734.27% | -139.21% | 1.7% | 22.93% | 46.33% | 36.54% |
FCF per Share | -0.74 | -0.51 | -0.53 | 0.11 | -0.57 | -1.25 | -1.09 | -0.74 | -0.38 | -0.38 |
FCF Conversion (FCF/Net Income) | 0.73x | 0.65x | 0.93x | 0.66x | 0.61x | 0.84x | 0.87x | 0.67x | 0.20x | 0.90x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PACB Key Ratios
Pacific Biosciences of California, Inc. (PACB) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -107.97% | -102.48% | -99.58% | 15.06% | -32.18% | -46.42% | -48.53% | -51.3% | -213.45% | -488.45% |
Return on Invested Capital (ROIC) | -111.42% | -103.23% | -76.62% | -40.9% | -19.96% | -18.64% | -18.99% | -27.59% | -45.83% | -17.83% |
Gross Margin | 37.08% | 31.92% | 38.04% | 41.28% | 45.1% | 38.22% | 26.32% | 24.21% | 31.67% | 37.08% |
Net Margin | -98.63% | -130.44% | -92.57% | 37.27% | -138.85% | -244.92% | -152.97% | -201.18% | -341.47% | -80.34% |
Debt / Equity | 0.16x | 0.13x | 1.12x | 0.13x | 1.21x | 1.68x | 1.33x | 1.33x | 141.98x | 297.29x |
Interest Coverage | -30.56x | -41.33x | -31.22x | 111.12x | -20.94x | -20.39x | -21.18x | -22.08x | -77.52x | -44.67x |
FCF Conversion | 0.73x | 0.65x | 0.93x | 0.66x | 0.61x | 0.84x | 0.87x | 0.67x | 0.20x | 0.90x |
Revenue Growth | 3.04% | -15.88% | 15.6% | -13.2% | 65.43% | -1.69% | 56.29% | -23.19% | 3.89% | 5.04% |
Related:PACB Dividend History·PACB Revenue History·PACB Price History·PACB P/E History·PACB Financial Ratios·PACB Institutional Holders
PACB SEC Filings & Documents
Pacific Biosciences of California, Inc. (PACB) SEC filings — annual & quarterly reports (10-K, 10-Q)
PACB Frequently Asked Questions
Pacific Biosciences of California, Inc. (PACB) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Pacific Biosciences of California, Inc. (PACB) reported $160.0M in revenue for fiscal year 2025. This represents a 17661% increase from $0.9M in 2008.
Pacific Biosciences of California, Inc. (PACB) grew revenue by 3.9% over the past year. Growth has been modest.
Pacific Biosciences of California, Inc. (PACB) reported a net loss of $128.6M for fiscal year 2025.
Dividend & Returns
Pacific Biosciences of California, Inc. (PACB) has a return on equity (ROE) of -213.5%. Negative ROE indicates the company is unprofitable.
Pacific Biosciences of California, Inc. (PACB) had negative free cash flow of $116.2M in fiscal year 2025, likely due to heavy capital investments.